UroGen Pharma (URGN) Retained Earnings (2016 - 2026)

UroGen Pharma (URGN) has reported Retained Earnings for 11 consecutive years, with -$983.3 million the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings fell 15.67% year-over-year to -$983.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$983.3 million (down 15.67% YoY) and the FY2025 annual result came in at -$959.7 million, down 19.04% from the prior year.
• Retained Earnings eased to -$983.3 million in Q1 2026 per URGN's latest filing, from -$959.7 million in the prior quarter.
• Over the last five years, Retained Earnings for URGN reached as high as -$495.7 million in Q1 2022 and fell as low as -$983.3 million in Q1 2026.
• A 5-year average of -$727.8 million and a median of -$711.6 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings dropped 29.62% — and 2026, when it slipped 15.67%.
• Year by year, Retained Earnings stood at -$577.1 million in 2022, then retreated by 17.72% to -$679.3 million in 2023, then declined by 18.68% to -$806.2 million in 2024, then retreated by 19.04% to -$959.7 million in 2025, then decreased by 2.46% to -$983.3 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$983.3 million, -$959.7 million, and -$933.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.